Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies
Overall, ICI resistance in GU cancers emerges as a multidimensional phenomenon with distinct biological drivers across tumor subtypes; precision combinations targeting both intrinsic tumor factors and the immunosuppressive TME represent the most promising avenue to overcome resistance, and standardization of composite...